LOI Deadline
Sponsor Deadline
Posted: 3/27/2024

Congressionally Directed Medical Research Programs (CDMRP) -- Peer Reviewed Medical Research Program -- Technology/Therapeutic Development Award

The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY24 PRMRP Topic Areas and one of the FY24 PRMRP Strategic Goals. Products in development should be responsive to the health care needs of military Service Members, Veterans, and their Families. The product(s) to be developed under the PRMRP TTDA mechanism may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. (A “knowledge product” is a non-materiel product that addresses an identified need in a topic area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)

Deadlines:
• Required Pre-Application Deadline:  May 13, 2024
• Application Submission Deadline:  June 6, 2024

Areas of Interest
  • AUTOIMMUNE DISORDERS AND IMMUNOLOGY
  • CARDIOVASCULAR HEALTH
  • INFECTIOUS DISEASES
  • INTERNAL MEDICINE
  • NEUROSCIENCE
  • ORTHOPAEDIC MEDICINE
  • RARE DISEASES AND CONDITIONS
  • RESPIRATORY HEALTH
Eligibility Requirements

PIs at or above the level of Assistant Professor (or equivalent) may be named by the organization as the PI on the application. An investigator may be named on only one FY24 PRMRP Technology/Therapeutic Development Award application as a PI.

Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY24 PRMRP Technology/Therapeutic Development Award should not exceed $4.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.